Evidence map›Paper›PMID 42648120›Full record

ArticleStem cell research2026

Generation of two induced pluripotent stem cell lines from Fabry disease patients carrying GLA mutations.

Debarun Patra, David G T Cabrera, Xiaochun Yang, Parker Walther, Souhrid Mukherjee, Jacinda Sampson, Joseph C Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Debarun PatraStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
David G T CabreraStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Xiaochun YangStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Parker WaltherGreenstone Biosciences, Palo Alto, CA 94305, USA.
Souhrid MukherjeeGreenstone Biosciences, Palo Alto, CA 94305, USA.
Jacinda SampsonStanford Neuroscience Health Center, Stanford University School of Medicine, Stanford, CA 94304, USA.
Joseph C WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: joewu@stanford.edu.

Funding

Project 3 (Mercola)P01HL141084 · NHLBI · STANFORD UNIVERSITY · PI Joseph C. Wu · 2019 to 2026
$21.1M
Advancing Personalized Cardiac Organoids - Converging In Vitro, In Chemico, and In Silico ModelsUM1TR006031 · NCATS · STANFORD UNIVERSITY · PI Afshin Beheshti, Sarah C Heilshorn · 2026 to 2026
$3.1M
AI-driven Drug Discovery Targeting Cardiac Fibrosis in Aging HeartUG3AG097135 · NIA · STANFORD UNIVERSITY · PI SAYED, NAZISH, WU, JOSEPH C. · 2025 to 2025
$900k
Development of 3D Multi-cellular Cardiac Tissues for Modeling Delayed Radiation-induced InjuryU01AI195484 · NIAID · STANFORD UNIVERSITY · PI Adam J Chicco, Joseph C. Wu · 2026 to 2026
$539k
NCATS NIH HHS UM1 TR006031NHLBI NIH HHS P01 HL141084NIAID NIH HHS U01 AI195484NIA NIH HHS UG3 AG097135
6 · The paper itself

Abstract

Fabry disease is a rare genetic disease caused by loss-of-function in the GLA gene. This gene encodes the lysosomal enzyme α-galactosidase A (α-Gal A). A deficiency of α-Gal A results in the globotriaosylceramide buildup throughout the major organs, which is associated with increased mortality from cardiac disease in patients with Fabry disease. Both females and males are affected by this X-linked disease. We generated and characterized induced pluripotent stem cell (iPSC) lines from peripheral blood mononuclear cells (PBMCs) of two female patients carrying a heterozygous GLA mutation. The two Fabry disease patient-derived iPSC lines are thoroughly characterized and genetically accurate, valuable human cell resources for preclinical research.

Indexed as

alpha-GalactosidaseFabry DiseaseInduced Pluripotent Stem CellsMutationAdultCell LineFemaleHumansLeukocytes, Mononuclearalpha-GalactosidaseGLA protein, humanFabry diseaseGLA mutationHuman induced pluripotent stem cellsiPSC biobankRare genetic disease

Identifiers

PMID42648120
PMCPMC13618801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.